Jason Chin
Directeur/Membre du Conseil chez GENUS PLC
Profil
Jason Chin is the founder of Constructive Bio Ltd.
He is currently working as an Independent Non-Executive Director at Genus Plc.
Postes actifs de Jason Chin
| Sociétés | Poste | Début |
|---|---|---|
| GENUS PLC | Directeur/Membre du Conseil | 01/04/2021 |
Constructive Bio Ltd.
 Constructive Bio Ltd. BiotechnologyHealth Technology Constructive Bio Ltd. is a British biotechnology company that rewrites genomes to create biomolecules that were previously unimaginable. The company is based in Cambridge, UK and is backed by a world-class syndicate of investors including Ahren Innovation Capital, Amadeus Capital Partners, OMX Ventures, and General Inception. The company is creating next-generation therapeutics and industrial solutions while setting the standard for genetic code reprogramming. With a world-class team in synthetic genomics and a passionate commitment to improving health and bioprocessing, Constructive Bio is reimagining the world of biologic therapies by rewriting the genome itself. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENUS PLC | Process Industries |
| Entreprise privées | 1 |
|---|---|
Constructive Bio Ltd.
Constructive Bio Ltd. BiotechnologyHealth Technology Constructive Bio Ltd. is a British biotechnology company that rewrites genomes to create biomolecules that were previously unimaginable. The company is based in Cambridge, UK and is backed by a world-class syndicate of investors including Ahren Innovation Capital, Amadeus Capital Partners, OMX Ventures, and General Inception. The company is creating next-generation therapeutics and industrial solutions while setting the standard for genetic code reprogramming. With a world-class team in synthetic genomics and a passionate commitment to improving health and bioprocessing, Constructive Bio is reimagining the world of biologic therapies by rewriting the genome itself. | Health Technology |
